Nanopore sequencing cuts time needed to identify fungal bloodstream infections

Bloodstream infections caused by fungi present clinical microbiology laboratories with a difficult combination of urgency and technical complexity. Appropriate antifungal treatment depends upon knowing which organism is responsible for the infection, yet conventional identification requires sufficient microbial growth to occur before the laboratory can move to more definitive testing.

 

By Tim Sandle 

 

Researchers at Chiba University in Japan have developed a genomic workflow intended to shorten this diagnostic interval. In a study published in Microbiology Spectrum, the researchers report species-level identification of fungal pathogens from blood culture samples in approximately seven hours, and importantly, before automated blood culture systems indicated that the samples were positive. The research is described by Chiba University.

 

This development is significant because rapid organism identification represents an important component of effective management of bloodstream infection. Different fungal species can respond differently to antifungal agents, making accurate identification relevant to the selection of appropriate treatment.

Getting ahead of blood culture positivity

Conventional blood culture depends upon microorganisms multiplying until their growth can be detected. According to the Chiba University researchers, culture followed by identification testing can take several days to complete. The new method takes a different approach. Instead of waiting for the culture instrument to signal positivity, the scientists remove a sample while the blood culture is still incubating and seek to recover and characterize microbial DNA directly.

 

The workflow developed by the group led by Hiroki Takahashi, Professor at the Medical Mycology Research Center, Chiba University, consists of three principal stages.

 

The first challenge is that blood contains a large quantity of human material. The researchers selectively break down human cells before using benzonase to degrade the released human DNA, while leaving fungal and bacterial DNA unaffected. This increases the relative proportion of microbial DNA available for subsequent analysis. The second stage uses PCR-based whole-genome amplification. This produces multiple copies of DNA fragments from across the genomes contained within the specimen and provides sufficient genetic material for sequencing. 

 

Finally, the amplified material undergoes nanopore sequencing. Rather than requiring the entire sequencing run to finish before analysis can begin, nanopore technology produces sequence data continuously. The resulting sequences are compared with a purpose-built reference database containing genomic information for fungal and bacterial organisms associated with bloodstream infections. This combination of sample preparation, amplification and real-time sequencing is what enables the researchers to seek an identification before conventional blood culture positivity.

Testing clinical blood cultures

The researchers evaluated the process using 48 clinical blood culture samples covering eight fungal species. Chiba University reports that species-level identification was achieved in approximately seven hours with high accuracy. Organisms identified included Candida albicans, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans and Nakaseomyces glabratus. The last organism is particularly familiar to laboratories under its former name, Candida glabrata, although the Chiba report uses the currently accepted Nakaseomyces nomenclature.

 

 

A further interesting feature was the ability to recognize more complicated specimens. The researchers detected mixed infections in some samples, including cultures containing two fungal species and others containing fungal and bacterial organisms. This is potentially important for diagnostic microbiology because a dominant organism can complicate the detection of other microorganisms within a mixed population. That difficulty has not been completely overcome. The researchers specifically identify heavy bacterial growth masking fungal signals in mixed infections as an area requiring further work. They also need to establish the optimum point during blood-culture incubation at which a specimen should be taken for genomic analysis. 

 

These limitations are important. The work demonstrates the potential of the approach, but it should not yet be interpreted as a replacement for established diagnostic workflows.

 

Genomics provides another layer of information

Species identification is not the only information potentially available from the sequencing process. Because the method obtains genomic information from the pathogen, the researchers state that it can identify genetic variants in genes associated with antifungal drug resistance. This presents an interesting direction for clinical microbiology. Rapidly determining the likely organism is valuable, but coupling identification with genomic information associated with resistance could make sequencing more useful for antimicrobial stewardship.

 

Phenotypic susceptibility testing and genomic resistance detection do not, however, answer precisely the same question. Consequently, the practical value will depend upon how reliably particular genetic markers predict clinically meaningful antifungal resistance and how genomic information is incorporated into validated laboratory procedures. The study itself is titled Random PCR-based nanopore whole-genome sequencing enables pre-positivity detection of fungal bloodstream infections and was published online on August 21, 2026, in Microbiology Spectrum.

Why speed matters

The technological advance needs to be considered in the context of treatment decisions. Until the causative microorganism is known, clinicians may need to make treatment decisions with incomplete microbiological information. Chiba University notes that during the conventional diagnostic interval patients may receive broad antifungal treatment, while more targeted therapy has to await further information. 

 

Faster microbiological identification therefore has the potential to reduce some of this uncertainty. “Our method may enable clinicians to initiate appropriate antifungal treatment earlier, potentially improving outcomes for patients with life-threatening fungal bloodstream infections,” Hiroki Takahashi states.

 

The word “may” is important. The present study demonstrates analytical and diagnostic potential. It does not, on the evidence reported by the university, demonstrate improved patient outcomes resulting from use of the workflow.

From proof of concept to routine microbiology

For pharmaceutical and clinical microbiologists, perhaps the most interesting aspect of the research is how several existing molecular technologies have been integrated around a particular diagnostic bottleneck. The significant step is not nanopore sequencing in isolation. It is the complete sample-to-identification strategy: removing unwanted host DNA, increasing microbial genomic material through amplification and exploiting real-time sequencing sufficiently early in blood-culture incubation to obtain information before the automated culture signal. 

 

There are still questions to address before such an approach could progress toward broader routine use. Chiba University says further validation is needed, together with work to optimize the sampling time and improve fungal detection where substantial bacterial growth is present. 

 

Nevertheless, the study illustrates a broader change taking place within diagnostic microbiology. Culture remains enormously important, but genomic technologies are increasingly creating opportunities to obtain actionable information without waiting for all of the traditional microbiological process to be completed.

 

For fungal bloodstream infections, where identifying the infectious agent is particularly important to choosing suitable antifungal therapy, moving identification even a day earlier could prove valuable. The Chiba University work suggests that it may be possible to move considerably further upstream, interrogating the microbial genome while the blood culture bottle is still incubating.

 

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

End-to-End Traceability in Sterility Testing: The Digital Path to Audit Confidence (webinar)

Regulatory expectations for data integrity and governance in QC laboratories are evolving rapidly—and sterility testing is no exception. In this expert panel, specialists in QC laboratory management, data integrity oversight, and solution development will explore what these expectations mean for laboratories today and how organizations can translate them into practical, site-level action.

Webinar details: 

• Friday, November 06, 2026
• 3:00 PM Central European Time
• 1 hour, 30 minutes

The discussion will follow the end-to-end journey toward audit-ready sterility testing: from recognizing the need for digital transformation to implementing traceable workflows and embedding sustainable data governance.

In the second part of the webinar, the experts will answer questions from the audience, bringing the discussion closer to your specific challenges and implementation priorities.

Three experts, one end-to-end perspective—from regulatory expectations to real-world execution.

In this webinar, you will:

• Understand the shift from data integrity to data governance and its implications for sterility testing and site-generated data.
  
  
• Recognize the critical elements of a robust data chain—including equipment, consumables, operators, methods, and LIMS.
  
  
• Understand how digital transformation enables end-to-end traceability, across the sterility testing workflow.
  
  
• Identify the key success factors for implementation and user adoption, including staff engagement, training, and change management. 
  
  
• Recognize the value of traceable data for investigations, continuous improvement, and audit readiness within a broader strategy for contamination control and sterility assurance.

For details, see The Digital Path to Audit Confidence.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Expert insights on BFPCs for Real-Time Air Monitoring

Recent regulatory changes and technological advances are leading pharmaceutical manufacturers to consider new technologies for microbial air monitoring. EU GMP Annex 1 requires continuous viable air monitoring in Grade A environments for the full duration of critical processing, and its recent revision has changed regulatory attitudes toward real-time detection. Manufacturing is evolving, too: novel biologicals are increasingly being produced with minimal operator intervention in gloved or even gloveless isolators.

These developments have catalyzed broader interest in advanced biofluorescent particle counters (BFPCs) for fluorescence-based continuous active air monitoring in real-time, available in combination with integrated traditional microbial air sampling onto plates. In this webinar, our panel of environmental monitoring specialists will discuss in which settings a BFPC can streamline workflows to boost manufacturing productivity while meeting present and future regulatory demands, and the challenges that need to be overcome.

During the webinar, you will:

• Discover real-time air monitoring in Grade A environments under the latest EU Annex 1.
• Learn how BFPCs pair with traditional sampling to enable real-time decisions.
• Understand regulatory, validation, and operational challenges.
• Explore practical options for integration, qualification, and cost/benefit considerations.

To register go to: BFPCs.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Laser Cleaning for Biofilm Removal in Pharmaceutical Processing Lines

 Image (C) Tim Sandle

This is the first of three articles extending the discussion of solvent-free decontamination begun in "Laser Cleaning in Pharmaceutical Manufacturing" (July 2026). Where that piece surveyed the method in general terms, this one narrows to the contaminant that most reliably defeats conventional cleaning: established biofilm.

Sanitisation and cleaning are not the same claim

Much of the confusion around biofilm control in pharmaceutical processing comes from conflating two distinct regulatory obligations. Sanitisation asks whether viable organisms have been inactivated. Cleaning asks whether residue has been removed to a defined limit. A biocide can satisfy the first while leaving the second entirely unaddressed.

This matters because biofilm is not primarily a population of cells. It is a structure — a hydrated matrix of extracellular polymeric substances (EPS), largely polysaccharide, protein and extracellular DNA, within which cells are embedded. When a sporicidal or oxidising agent passes over that structure, the cells within it may well be killed. The matrix, and the killed biomass inside it, remains adhered to the surface.

From a cleaning validation standpoint, that material is residue. It is organic carbon on a product-contact surface. It will register on total organic carbon (TOC) rinse analysis. It remains a nutrient reservoir and an adhesion scaffold, so the surface is preferentially recolonised — which is the usual explanation when a water system returns to alert levels within days of a successful sanitisation cycle.

Why the matrix resists chemistry

Three mechanisms are well described in the literature and worth restating in a cleaning context.

First, diffusion limitation. The EPS matrix retards the penetration of biocide to the deeper cell layers, so the effective concentration reaching the substrate interface is lower than the concentration applied. Contact time specified from planktonic suspension testing therefore systematically understates what an adherent biofilm requires.

Second, reaction and neutralisation. Oxidising agents are consumed by the outer matrix itself. The material closest to the stainless steel — the layer that actually determines whether the surface is clean — is the last to be reached and the least aggressively treated.

Third, phenotypic tolerance. Cells in the sessile state express a physiology markedly different from their planktonic counterparts, including reduced metabolic rate in the deeper strata, and are correspondingly less susceptible to agents whose action depends on active metabolism.

The practical consequence is familiar to anyone who has investigated a recurring bioburden excursion: the cycle passes, the rinse sample passes, and the organism returns. The organism returns because its house was never demolished.

What laser ablation does differently

Pulsed laser cleaning is not a disinfection process. It is a removal process, and that is precisely the point of interest here.

The mechanism was outlined in the earlier article: a pulsed source, typically operating around 1064 nm, delivers energy in discrete packets to the surface. Removal depends on the differential absorption between the layer to be removed and the substrate beneath it. Electropolished 316L stainless steel is strongly reflective at that wavelength; hydrated organic material is not. Energy is therefore preferentially deposited in the contaminant.

For biofilm specifically, the water content of the matrix is an advantage rather than an obstacle. Rapid, localised energy deposition produces vaporisation and mechanical spallation within the EPS layer, so the matrix is lifted from the surface as particulate and vapour and drawn away by local extraction. Cells and matrix are removed together, as a single layer. There is no distinction between killed and living material, because neither is left behind.

Two secondary properties follow from this, both relevant to a contamination control strategy:

The process is dry. No cleaning agent is introduced, so no cleaning agent requires its own removal validation — the point made under ICH Q7 Section 12.7 in the earlier article applies with equal force here. Equally, no rinse step is required, which removes one water-contact operation, and therefore one recolonisation opportunity, from the sequence.

The process is monitorable. Because ablation produces a characteristic acoustic and optical emission that changes as the contaminant layer is cleared and the substrate is reached, end-point detection is at least in principle available in real time, rather than only through offline swab and rinse sampling.

Where it fits, and where it does not

It would be misleading to present laser ablation as a general replacement for clean-in-place. It is a line-of-sight method. It cannot address the interior of installed pipework, a dead leg, or the inner geometry of a closed system, and no configuration of optics changes that constraint.

The realistic applications are surfaces that can be presented to the beam: dismantled filling line components, gaskets and seal faces, vessel interiors with adequate access, transfer and change parts, and equipment removed from service for investigation or refurbishment. In water systems, the honest positioning is not as a CIP substitute but as a remediation step for components taken out of the loop, and for the accessible surfaces of tanks and distribution points where an established biofilm has proved refractory to repeated sanitisation.

Two further limitations deserve to be stated plainly. Particulate is generated and must be captured; extraction and filtration are part of the equipment, not an optional accessory. And surface finish must be verified rather than assumed: parameters selected below the ablation threshold of the substrate should leave roughness unchanged, but this is a matter for demonstration during process development, with Ra measurement before and after, not a property to be taken on trust.

Verifying removal rather than inactivation

Because the claim is removal, verification should be built around removal endpoints.

A defensible package would combine direct surface sampling — swabs and contact plates for viable recovery — with TOC on a defined rinse or extraction, since TOC responds to matrix material that viable counts will miss entirely. Where the question is specifically whether the structure has gone, microscopy of coupons carrying a grown biofilm is the most direct evidence available, and scanning electron microscopy or confocal imaging of treated versus untreated coupons is far more persuasive to an inspector than a plate count.

Coupon studies using a defined organism grown to an established biofilm under controlled conditions, then treated and examined, provide the underlying evidence. Recovery studies for the analytical method, and a demonstration that results are reproducible across operators and across the geometry of the actual part, complete the picture in the usual way.

The regulatory framing

None of this sits outside existing expectations. EU GMP Annex 1 (2022) requires a documented contamination control strategy and asks manufacturers to justify the methods within it; a non-chemical, non-contact removal step is straightforward to describe in those terms, particularly where it reduces interventions. Section 6 of the same annex, covering utilities, is explicit about the need to control biofilm in water systems, and a method aimed at the matrix rather than at viability addresses that requirement directly.

ICH Q7 Section 5.2 requires equipment cleaning procedures to be adequate and documented, and Section 12.7 sets the expectations for cleaning validation. A process that introduces no cleaning agent simplifies the residue calculation under the health-based exposure limit framework, because the only residue at issue is the one being removed.

Part 2 will take this comparison into the cleanroom itself, setting laser cleaning against solvent-based and CIP methods in an ISO Class 5 context, with particular attention to particle generation and the documentation burden each approach carries.

Alex Chen writes on industrial surface decontamination and works with laser cleaning system manufacturers supplying regulated industries. Further technical material on laser cleaning for manufacturing is available at LaserCleanerPro.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Pharmaceutical Water Systems Under Greater Microbiological Scrutiny: Emerging Monitoring and Risk-Management Strategies

Pharmaceutical water systems can produce acceptable microbiological results while still developing conditions that warrant closer investigation. A culture result describes what was recovered from one sample under particular test conditions. It does not necessarily reveal what is occurring elsewhere in a storage vessel, distribution loop, membrane surface, valve, branch connection, or point-of-use assembly. 

That distinction matters because the microbiological condition of a water system can change with temperature, circulation, production demand, sanitisation, maintenance and periods of reduced use. WHO guidance consequently places emphasis on representative sampling, ongoing monitoring, trend analysis and periodic review of water-system performance rather than relying on isolated test results. 

Greater scrutiny, therefore, should not be interpreted simply as collecting more samples. More useful assurance comes from understanding whether microbiological findings remain consistent with the way the system is operating and whether small changes are being recognised before they develop into recurring excursions. 

A compliant sample does not describe the whole system 

Microbiological risk can change between the point at which water is generated and the point at which it is used. Storage vessels, distribution loops and individual points of use introduce different physical conditions, and the same water may behave differently in sections with different flow, turnover or usage patterns. 

FDA guidance on high-purity water systems notes that microorganisms can occur both as free-floating cells and as biofilms attached to surfaces, with attached populations capable of continually releasing organisms into the water. Contamination may therefore be unevenly distributed within a system. 

That makes location an important part of interpretation. 

• An acceptable result at generation: It provides evidence about the treatment stage, but not necessarily about downstream distribution. 

• A change at one point of use: It may direct attention toward local piping, fittings, hoses, flow conditions, sampling technique, or nearby surfaces.

• Similar changes across several locations: They are more difficult to explain as a single point-specific event and may warrant review of a wider part of the loop.

• An unusual organism: Identification can provide context that a colony count alone cannot, particularly when a similar organism appears repeatedly.

Pharmaceutical Microbiology Resources has previously highlighted how seasonality, temperature, velocity, system design, and maintenance can influence microbial contamination in pharmaceutical water systems. 

The implication is important: microbiological results should be read against the physical system that produced them. 

Trend analysis should look for movement, not just excursions 

A water system does not need to exceed an action limit before its behaviour becomes interesting. 

Imagine a sampling point that has historically produced low, stable recoveries. Across several monitoring cycles, counts begin to rise, although every result remains within the established range. Nothing has formally failed, yet the baseline has changed. 

That is where trend analysis becomes useful. 

WHO guidance recommends routine trend analysis and the use of historical data when establishing and reassessing alert and action levels. The most useful trend review can bring several variables together: 

• Count: Is the microbial level moving away from its established baseline?

• Frequency: Are higher recoveries occurring more often?

• Location: Is the change isolated or appearing across connected points?

• Identity: Are similar organisms recurring?

• Timing: Did the pattern begin after maintenance, sanitisation, shutdown, or a use change?

• Operating data: Did flow, temperature, conductivity, TOC, or another relevant parameter change at a similar time?

Such analysis is more informative than simply plotting CFU values against dates. A gradual shift that remains within specification may be a very different signal from a single isolated excursion followed by an immediate return to baseline. 

Alert levels also need to remain system-specific. Historical performance, qualification data, and investigation results provide a stronger basis for setting and reviewing those levels than simply adopting a generic number from another facility. 

The sampling plan should reflect how the water is actually used 

Representative sampling is not achieved merely by placing sample points at convenient locations.  Generation, storage, distribution and point-of-use locations provide different types of evidence. A treatment-stage sample may demonstrate that the purification process is producing water of the intended quality, while a point-of-use sample can reveal what happens after that water has travelled through the distribution network. 

WHO guidance calls for sampling at points of use or suitable dedicated sample points and for consistent sampling methods. 

An effective programme should therefore be able to answer three practical questions: 

1. Coverage: Are the locations capable of detecting changes in the different parts of the system? 

2. Frequency: Does the schedule reflect the history, intended use and risk profile of each part of the system?

3. Consistency: Are flushing, collection, handling, and testing procedures sufficiently controlled to make results comparable over time?

Frequency deserves particular attention. More frequent sampling is not automatically more informative if the locations are poorly chosen or the results cannot be interpreted consistently. Conversely, a long-established system may need additional sampling following an intervention, abnormal trend, prolonged shutdown, or significant modification. 

FDA guidance has also emphasised the value of point-of-use sampling because microbial contamination can occur within the distribution system after water has passed through the primary treatment stages. 

In other words, the sampling network should tell the story of the system rather than merely satisfy a schedule. 

Downtime can create a different microbiological state 

Extended downtime deserves more attention than it often receives because system conditions during inactivity are not necessarily representative of normal production. 

Recent research into pharmaceutical water-treatment equipment has reported that downtime can create conditions associated with membrane biofouling, including abrupt flow reductions, changes in dissolved oxygen, and nutrient accumulation. Such changes may encourage microbial colonisation and influence later membrane performance. 

A return-to-service event should therefore be viewed as a transition that may require its own assessment. 

• Before restart: What remained filled or stagnant during the interruption? 

• During restart: What flushing, recirculation or sanitisation sequence was used?

• Immediately afterward: Do early samples resemble the established microbiological baseline?

• During subsequent operation: Does the system remain stable, or does an unusual pattern emerge after several cycles?

The last question is easily overlooked. One acceptable sample after restart does not necessarily establish that the system has fully returned to its previous condition. Later results may provide a more useful indication of whether control has actually been restored. 

Broader water-treatment investment is also moving toward more sophisticated monitoring and treatment infrastructure. India's membrane water and wastewater treatment market, for example, was valued at about USD 520 million in 2025 and is projected to reach USD 891.2 million by 2032, with an estimated 8% CAGR. 

That broader development does not translate directly into pharmaceutical water requirements, but it illustrates the scale of investment in treatment infrastructure and the growing importance of systems that can maintain consistent process performance under changing operating conditions. 

Repeated recovery changes the investigation 

Recurring microbial recovery from one location should not automatically be labelled as biofilm. It should, however, change the questions being asked. FDA guidance describes biofilm-associated organisms as a possible continuing source of contamination because attached populations can release microorganisms back into the water. 

Where the same location repeatedly generates unusual findings, investigators can examine: 

• Hydrodynamics: Is circulation adequate, or could the location experience low flow or poor turnover? 

• Hardware: Could valves, branches, fittings, gaskets, or other components create difficult-to-sanitise surfaces?

• Sanitisation: Does the selected intervention reach the relevant area under actual operating conditions?

• Maintenance: Has the location been opened, modified, or repaired?

• Sampling: Could the sampling process itself be introducing variability?

The maintenance history can be especially valuable. Pharmaceutical Microbiology Resources has previously discussed intervention-related contamination risks, including work involving valves and pipework. 

For microbiology teams, that means engineering records should not be treated as separate documentation that becomes relevant only during a formal deviation. When an unusual organism repeatedly appears at one location, maintenance and change-control history may provide the missing explanation. 

Online monitoring is valuable when it adds context 

The wider water-quality market is already moving toward more continuous monitoring. Online water-quality monitoring systems accounted for 25% of the broader water-quality testing and monitoring market in 2025, reflecting growing demand for continuous visibility rather than reliance solely on periodic measurements. 

Pharmaceutical manufacturing has good reason to examine that direction carefully, but not to confuse greater data frequency with microbiological assurance. 

WHO guidance supports the use of online monitoring for parameters such as temperature, flow, pressure, conductivity and TOC alongside offline physical, chemical and microbiological testing. The real benefit appears when those datasets are interpreted together. A change in flow may provide context for a later rise in microbial recovery. A temperature deviation may help explain why one period produced different results from another. A conductivity change may indicate an upstream process problem that would otherwise appear disconnected from downstream observations. 

No single parameter proves the cause of a microbiological event. Combined evidence can, however, narrow the investigation considerably. Rapid microbiological methods can shorten the delay between sampling and detection. Pharmaceutical Microbiology Resources has previously described rapid detection approaches for pharmaceutical-grade water as an alternative to conventional methods with longer time-to-result. 

Their value depends on method suitability, validation, and appropriate interpretation. A faster result is useful only when it represents meaningful information about the microbiological question being investigated. 

An excursion should connect the laboratory result to the system history 

Repeat testing may be necessary after an unexpected result, but a repeat sample should not become the entire investigation. 

WHO inspection guidance points toward a wider review that can include the water-system diagram, sampling programme, alert and action levels, trend data, periodic system review, changes, deviations, maintenance and repair records, and calibration of critical instruments. 

A practical investigation can therefore proceed in stages: 

• Verify: Confirm that sampling, transport, laboratory controls and test execution were satisfactory. 

• Localise: Determine whether the finding is limited to one point, branch or equipment component. 

• Compare: Review historical counts, organism identity and trends from the affected location.

• Reconstruct: Examine maintenance, sanitisation, shutdowns, modifications and deviations around the event.

• Correlate: Compare microbiological findings with relevant operating parameters.

• Confirm control: Assess whether corrective action produces sustained improvement rather than one acceptable follow-up result.

That final distinction matters. A temporary reduction in microbial counts does not necessarily demonstrate that the underlying cause has been removed. Sustained performance provides stronger evidence that control has actually been restored. 

Building a stronger picture of microbiological control 

Pharmaceutical water assurance is becoming less dependent on any single measurement and more dependent on how different pieces of evidence fit together. 

Microbial counts and organism identity remain central. Sampling location determines what those results can represent. Trend analysis shows whether behaviour is stable or changing. Engineering and operational records provide context. Online parameters can help identify when the physical state of the system has shifted, while rapid microbiological methods can reduce the time between detection and response.  The strongest monitoring programmes connect all of those elements. 

A compliant sample remains important, but compliance at one moment does not by itself demonstrate sustained control. Greater microbiological scrutiny is ultimately about recognising meaningful changes earlier, understanding why they may have occurred, and determining whether corrective measures have restored the system rather than merely produced another acceptable test result. 

For pharmaceutical manufacturers, that is the difference between testing the water and demonstrating control of the water system that produces and distributes it. 

About the Author 

Shammi Thakur is Research Director at Vyansa Intelligence, with more than 15 years of experience in strategic market intelligence, industry research, forecasting, and competitive analysis across healthcare, pharmaceuticals and biotechnology. His work focuses on translating complex industry developments into practical insights for business and industry professionals. 

 

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)